DE60324535D1 - Morpholinyl-harnstoff-derivative fuer die behandlung von krankheiten verbunden mit entzuendlichen prozessen - Google Patents

Morpholinyl-harnstoff-derivative fuer die behandlung von krankheiten verbunden mit entzuendlichen prozessen

Info

Publication number
DE60324535D1
DE60324535D1 DE60324535T DE60324535T DE60324535D1 DE 60324535 D1 DE60324535 D1 DE 60324535D1 DE 60324535 T DE60324535 T DE 60324535T DE 60324535 T DE60324535 T DE 60324535T DE 60324535 D1 DE60324535 D1 DE 60324535D1
Authority
DE
Germany
Prior art keywords
morpholinyl
treatment
diseases associated
urea derivatives
defensive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60324535T
Other languages
German (de)
English (en)
Inventor
Rachael Ann Stevenage Ancliff
Caroline Mary Cook
Colin David Eldred
Paul Martin Gore
Lee Andrew Harrison
Martin Alistair Hayes
Simon Teanby Hodgson
Duncan Bruce Judd
Suzanne Elaine Keeling
Xiao Qing Lewell
Gail Mills
Graeme Michael Robertson
Stephen Swanson
Andrew John Walker
Mark Wilkinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207434A external-priority patent/GB0207434D0/en
Priority claimed from GB0301608A external-priority patent/GB0301608D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE60324535D1 publication Critical patent/DE60324535D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE60324535T 2002-03-28 2003-03-27 Morpholinyl-harnstoff-derivative fuer die behandlung von krankheiten verbunden mit entzuendlichen prozessen Expired - Lifetime DE60324535D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0207434A GB0207434D0 (en) 2002-03-28 2002-03-28 Novel compounds
GB0301608A GB0301608D0 (en) 2003-01-24 2003-01-24 Novel compounds
PCT/EP2003/003335 WO2003082861A2 (en) 2002-03-28 2003-03-27 Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
DE60324535D1 true DE60324535D1 (de) 2008-12-18

Family

ID=28676494

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60324535T Expired - Lifetime DE60324535D1 (de) 2002-03-28 2003-03-27 Morpholinyl-harnstoff-derivative fuer die behandlung von krankheiten verbunden mit entzuendlichen prozessen

Country Status (23)

Country Link
US (1) US7622464B2 (enExample)
EP (1) EP1487828B1 (enExample)
JP (1) JP4465195B2 (enExample)
KR (1) KR20040093488A (enExample)
CN (1) CN1656092A (enExample)
AR (1) AR040403A1 (enExample)
AT (1) ATE413399T1 (enExample)
AU (1) AU2003226757A1 (enExample)
BR (1) BR0308780A (enExample)
CA (1) CA2480106A1 (enExample)
CY (1) CY1108652T1 (enExample)
DE (1) DE60324535D1 (enExample)
DK (1) DK1487828T3 (enExample)
ES (1) ES2315519T3 (enExample)
IL (1) IL164047A0 (enExample)
IS (1) IS7444A (enExample)
MX (1) MXPA04009459A (enExample)
NO (1) NO20044448L (enExample)
PT (1) PT1487828E (enExample)
RU (1) RU2004127928A (enExample)
SI (1) SI1487828T1 (enExample)
TW (1) TW200400035A (enExample)
WO (1) WO2003082861A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050100615A (ko) 2003-01-14 2005-10-19 싸이토키네틱스, 인코포레이티드 화합물, 조성물 및 방법
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
CA2559665A1 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
NZ552404A (en) 2004-06-17 2010-04-30 Cytokinetics Inc Compounds, compositions and methods
EP2289560B1 (en) * 2004-07-08 2015-04-22 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
JP4970946B2 (ja) 2004-09-08 2012-07-11 田辺三菱製薬株式会社 モルホリン化合物
NZ554555A (en) 2004-10-20 2011-09-30 Univ California Cyclohexyl-urea derivatives as improved inhibitors for the soluble epoxide hydrolase
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
EP1959960B1 (en) 2005-12-15 2013-04-10 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007078839A2 (en) 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
WO2009029632A1 (en) 2007-08-27 2009-03-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
WO2012054093A2 (en) 2010-01-29 2012-04-26 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
RU2512293C1 (ru) * 2012-12-13 2014-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный технический университет" Способ получения этил 1,2,4-оксадиазол-5-карбоксилатов
CN107362362B (zh) * 2017-07-20 2019-01-01 复旦大学 Sirt1抑制剂在预防和治疗放射引起的肠道疾病中的应用
EP4178948A2 (en) * 2020-07-29 2023-05-17 Universidade de Santiago de Compostela Functionalized isonitriles and products, preparation and uses thereof
WO2022031735A1 (en) * 2020-08-03 2022-02-10 Global Blood Therapeutics, Inc. Urea derivatives as pyruvate kinase activators
CN119330881A (zh) * 2024-09-06 2025-01-21 苏州汉德创宏生化科技有限公司 一种3-氨甲基-1-h吡唑的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851526A (en) 1987-09-04 1989-07-25 Schering A.G. 1-(4-Substituted phenyl)-1H-imidazoles compounds
JP3087763B2 (ja) 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
US5219856A (en) 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
WO1995032196A1 (en) 1994-05-19 1995-11-30 Merck Sharp & Dohme Limited Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
EP0772611A1 (de) 1994-07-20 1997-05-14 Byk Gulden Lomberg Chemische Fabrik GmbH Piperazinothiopyridine zur bekämpfung von helicobacter-bakterien
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
JP3531169B2 (ja) 1996-06-11 2004-05-24 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
IT1293807B1 (it) 1997-08-01 1999-03-10 Recordati Chem Pharm Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
US6031097A (en) 1997-10-27 2000-02-29 Neurogen Corporation 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
AU1122399A (en) 1997-10-27 1999-05-17 Neurogen Corporation Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands
CN1325397A (zh) 1998-09-30 2001-12-05 纽罗根公司 2-哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体
CZ20031195A3 (cs) 2000-09-29 2003-09-17 Glaxo Group Limited Morfolinacetamidové deriváty
ES2275729T3 (es) 2000-09-29 2007-06-16 Glaxo Group Limited Compuestos utiles en el tratamiento de enfermedades inflamatorias.

Also Published As

Publication number Publication date
WO2003082861A2 (en) 2003-10-09
CY1108652T1 (el) 2014-08-13
EP1487828B1 (en) 2008-11-05
RU2004127928A (ru) 2005-06-27
CN1656092A (zh) 2005-08-17
IL164047A0 (en) 2005-12-18
WO2003082861A3 (en) 2004-03-11
US20060063765A1 (en) 2006-03-23
MXPA04009459A (es) 2005-01-25
ES2315519T3 (es) 2009-04-01
CA2480106A1 (en) 2003-10-09
EP1487828A2 (en) 2004-12-22
DK1487828T3 (da) 2009-02-02
SI1487828T1 (sl) 2009-04-30
AR040403A1 (es) 2005-04-06
IS7444A (is) 2004-09-13
PT1487828E (pt) 2009-01-06
TW200400035A (en) 2004-01-01
BR0308780A (pt) 2004-12-28
JP2005526815A (ja) 2005-09-08
KR20040093488A (ko) 2004-11-05
US7622464B2 (en) 2009-11-24
AU2003226757A1 (en) 2003-10-13
NO20044448L (no) 2004-10-26
ATE413399T1 (de) 2008-11-15
JP4465195B2 (ja) 2010-05-19

Similar Documents

Publication Publication Date Title
DE60324535D1 (de) Morpholinyl-harnstoff-derivative fuer die behandlung von krankheiten verbunden mit entzuendlichen prozessen
DE60325209D1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
DE60325498D1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
ATE441417T1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
NL1026329A1 (nl) 2-Amino-pyridinederivaten toepasbaar voor de behandeling van ziekten.
ATE344253T1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60311272D1 (de) Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten
ATE316077T1 (de) Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
EP1622633A4 (en) Treatment of t-cell mediated diseases
DE60219292D1 (de) Pyrazolderivate zur behandlung von hiv
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
DE60100625D1 (de) Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
ATE516037T1 (de) Topische formulierung von ivermectin zur behandlung von dermatologischen erkrankungen
NL1026327A1 (nl) 2-Amino-pyridinederivaten toepasbaar voor de behandeling van ziekten.
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
NO20045554L (no) Fremgangsmate for behandling av diabetes
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne

Legal Events

Date Code Title Description
8364 No opposition during term of opposition